

Index

A

Abdominal Doppler US, 47
Abdominal imaging, 63
Abdominal pain, 45
Abelson gene (ABL) mRNA, 275
Actinomycin D, 87, 96, 98, 105
Adaptive immune cells, 193
Adjuvant chemotherapy, 87, 96, 116
Adults, WT in, 26, 217
AFP (alpha-fetoprotein), 86
Age as a prognostic factor, 26, 27
Allogeneic stem cell transplantation (allo-SCT), 275, 277, 278
Alternative lengthening of telomeres (ALT) mechanism, 36
Anaplasia, 8, 10, 24, 26, 65, 66, 192
Anaplastic histology, 9, 65, 96, 194, 195
Anaplastic Wilms' tumours, 8, 9, 10
Androgen receptor element half-sites (ARE-I), 245
Anthracyclines, 70, 98, 135
Antigen-presenting cells (APCs), 114, 154
APC membrane recruitment protein 1 (AMER1), 152
Appearance, 5, 16
Arterial hypertension, 140
Arterial line, 49
Aspirin, 167, 168, 169, 177

B

B lymphocytes (CD20+), 194
B7-H1 expression, 198
Beckwith–Wiedemann syndrome (BWS), 34, 44, 46, 134

Beta-catenin, 34, 152, 154, 155
 β HCG (beta-human chorionic gonadotropin), 86
Bilateral Wilms tumours (BWTs), 51, 61, 62, 132, 134
Blastema, 5, 6, 8, 16, 83
Blastemal-type WTs, 4, 6, 7, 13, 15, 16, 156
Brenner theory, 136

C

Cancer vaccination, 114, 115, 267
Canonical Wnt pathway, 152, 154, 155
Carbonic anhydrase IX (CAIX), 199
Carboplatin, 66, 105
Cardiac development, WT1 in, 212
Cavitron ultrasonic surgical aspirator, 67
CD3+ T cells, 193
CD4⁺ helper T cell, 114, 115
CD8⁺ killer T cell, 114
CD20+ B-cell infiltration, 194
CD34+ cells, 280
CD34+ hematopoietic progenitor cells, 238
CD44, 198
CD68+ macrophages (CD68M \emptyset), 194
Chemokines, 197, 199
Chemotherapy, 6, 24, 36, 51, 64, 65, 66, 78, 87, 98, 103, 105, 106, 119, 136
Chemotherapy before surgery strategy, 25
Chemotherapy-induced change (CIC), 7
Chest X-ray, 45
Childhood ERWTs, 78, 79, 88
Children, WT in, 26
Children's Oncology Group (COG), 24, 46, 62

Index

Chromatin immunoprecipitation (ChIP)
assay, 174, 242
Chromosome 11p13, 34
Chronic kidney disease (CKD), 131, 132,
135, 136, 137, 140
CITED1, 198
Clinical presentation, 45, 85
Clinical relevance of age, 25
c-Myc promoter, 172
COG staging system, 13
Color Doppler ultrasonography, 100, 103
Common Terminology Criteria for
Adverse Events (CTCAE), 119
Completely necrotic WT, 7
Components of Wilms tumor, 191
Computerized tomography (CT), 45, 46
Conventional chemotherapy, WT1
expression after, 275, 276, 277, 279
CREB-binding protein (CBP), 156, 237
Cut surface of tumour, 5
Cyclooxygenase-2 (COX-2) expression,
192, 195, 196, 199, 200, 201, 202
Cyclophosphamide, 53, 105
Cystic nephroma (CN), 16
Cystic partially differentiated
nephroblastoma (CPDN), 16
Cystic WTs, 16
Cytogenetics, 277
Cytokines, 190, 192, 193, 197
Cytotoxic T cells (CTLs), 116, 121

D

Dactinomycin, 66
Dendritic cells (DCs), 113, 114, 115, 117, 122
Denys-Drash syndrome (DDS), 34, 44, 65,
72, 133, 220, 236
Diagnosis, 3, 5, 14, 32, 45, 78, 85
Differential diagnosis, 3, 14, 16, 32, 36, 37, 87
Diffuse hyperplastic perilobar
nephroblastomatosis, 13

Dimethyl sulfoxide (DMSO), 245
Donor lymphocyte infusions (DLIs), 278
Doppler, ultrasound with, 47, 63
Doxorubicin, 66, 87, 98, 105
Drosophila PCP signaling, 153

E

Early growth response 1 (Egr1), 169, 170,
171, 172, 173, 175
E-cadherin, 151, 215, 237, 238, 240, 241, 248
18F-FDG-PET-CT imaging, 64
Electrophoretic mobility shift assay
(EMSA), 242
Embryonic development of kidney, 32
Embryonic nephrogenic tissue, 83
Endothelial cells, 215, 217, 218, 219, 220, 221
End-stage renal disease (ESRD), 132
Enhancer of zeste homolog 2 (EZH2), 237
Enzyme-linked immunosorbent spot
(ELISPOT) assays, 120
Ependymoma, 264
Epicardium-derived cells (EPDCs), 213
Epithelial cells, 151
Epithelial to mesenchymal transition
(EMT), 213, 237
Epithelial-type WT, 7, 16
Estrogen receptor (ER)-binding sites, 243
Etoposide, 53, 105, 122
Event-free survival (EFS) time, 100
Ewing sarcoma, 16
Extracellular matrix (ECM), 216
Extracellular signal-regulated protein
kinase (ERK) activation, 164
Extrarenal Wilms' tumor (ERWT), 77, 84,
85, 86

F

Favorable histology, 27, 33, 84, 88, 192
Features of WT, 15

Index

Fillet, 70
5-F Pigtail catheter, 97
Foley catheter, 49
4-F/5-F Cobra catheter, 98
Foxd1-positive cells, 33
Frasier syndrome, 236
Frizzled (FZD) family receptor, 152

G

Gain-of-function mutations, 34
Gemcitabine, 123
Gene activation/inactivation, 150
Gene expression in WT, 149
Genetic abnormalities in WT, 33
Gerota fascia, 49, 67, 70
Glioblastoma, 262, 263, 265
Glioma, 263
Glomerulosclerosis, 34
G-protein-coupled receptor (GPCR)
 superfamily, 164
Granulocyte colony-stimulating factor
 (G-CSF), 123
Granulocyte-macrophage colony-
 stimulating factor (GM-CSF), 115
Green fluorescent protein (GFP)-tagged
 WT1 expression, 243
Gross appearance, 5

H

HIF-1 α , 195
High telomerase reverse transcriptase
 (hTERT) staining, 36
Histological components of WT, 36
Histological features, 5–9
Histology, 3
Histopathological characteristics, 31
Histopathological features, 34
HLA-A*24:02 tetramer, 120
Horseshoe kidney and ERWT, 85

Human leukocyte antigen (HLA)
 molecules, 114, 267
Human thromboxane A₂ receptor gene,
 163
Hyperplastic perilobar
 nephroblastomatosis, 14, 15
Hyperplastic rests, 63
Hypertension, 135
Hypertrophy of a solitary kidney, 140
Hypoxia-inducible factor-1-alpha
 (HIF1 α), 219, 241

I

Ice-bath kidney cooling, 67, 68, 69
Ifosfamide, 53, 105
IL-4, 115
Immature DCs, 117
Immune cell infiltration, 193, 199
Immune cells, cross talk between, 199
Immune monitoring with tetramer
 analysis, 120
Immunohistochemical stains, 37
Immunosuppressive therapy, 278
Inducible nitric oxide synthase (iNOS), 197
Infants, WT in, 25
Infarcted heart, WT1 in, 216
Inflammation, WT and, 193
Inflammatory mediators, 195
Inflammatory microenvironment in WT, 189
Inguinal ERWT, 87
Innate immune cells, 194
Interleukin 10, 199
Intracardiac extension of WT, 51
Intralobar nephrogenic rest (ILNR), 12
Intravenous chemotherapy, 98

K

Ki-67 index, 36
Kidney cancer, 192

Index

Kidney damage, 136, 137
Kidney development, 151
Kocher' maneuver, 49

L

Laser capture microdissection (LCM), 239
LNCaP cells, 241
Lymph node sampling, 49

M

Macrophages, 194
Magnetic resonance imaging (MRI), 45
Malignant brain tumors, WT1
 expression in, 261
Malignant glioma, 267
Malignant renal tumors, 32, 33
Management of WT, 47
Manufacture of DC vaccine, 116
Mast cells (MCs), 193, 194
Matrix metalloproteinases (MMPs), 221
Mature DCs (mDCs), 116
Medulloblastoma, 264
Meningioma, 264
Mesenchymal cells, 151
Mesenchymal–epithelial
 transition (MET), 151, 237
Mesonephros, 83, 85
Metanephric adenoma, 37
Metanephric kidney, 33
Metanephric mesenchyme (MM),
 197, 198
Metastatic disease, 239
Microdeletion 11p13 syndrome, 132
MicroRNA (miRNA) biogenesis, 151
Minimal residual disease (MRD), 275
Minimal residual disease marker,
 WT1 as, 275, 277
Mithramycin A, 246
Molecular characteristics of WT, 31

Monophasic WTs, 14
Multicentric tumours, 5, 10
Multifocal NRs, 13
Multiparameter flow cytometry
 (MFC), 275
Mutation repertoire, 155
MYCN gene, 9

N

Nasogastric tube, 49
National Wilms Tumor Study (NWTS),
 46, 47, 50, 86, 100
National Wilms Tumor Study Group
 (NWTSG), 46, 51, 52
Necrotic WT, 7
Neoadjuvant transcatheter arterial
 chemoembolization, 95
Neoadjuvant chemotherapy, 66
Nephrectomy specimen, 9
Nephroblastoma, 4, 32, 44, 62
Nephroblastomatosis, 12, 13,
 14, 15, 63
Nephrogenesis, 151
Nephrogenic rests (NRs), 5, 12, 63, 83
Nephrons, 33
Nephron-sparing surgery (NSS), 48, 50,
 63, 134
Nestin, expression of, 221
Neuroblastoma (case), 119
Neutrophils, 194
NF-E2, 169, 177
Nitrotyrosine (NT), 197
Noncanonical Wnt signaling pathway,
 152, 154
Nonmetastatic WT, 25
Non-viable tumour, 11
Non-Wilms cancer, WT1 expression in,
 238
Non-WT renal tumors, 36
Non-WT1-syndromic BWTs, 134

Index

O

Oligodendroglioma, 263
Oncogenes, 151
Overall survival (OS) time, 100

P

Paediatric renal tumours, 9
Papillary renal cell carcinoma, 16
Pathogenesis of WT, 33
Perilobar nephrogenic rest (PLNR), 12, 156
Perioperative US, 51
Peritoneal reflection covering right
 Wilms tumor, 51
PERK1/2 protein, 196
Phosphorylated pERK1/2, 196
Phosphorylated-Stat3 (p-Stat3)
 expression, 196
Phycoerythrin (PE)-conjugated human
 immunodeficiency virus, 120
Pirarubicin, 98
Planar cell polarity (PCP) pathway, 152
Platelet endothelial cell adhesion
 molecule-1 (PECAM-1), 220
Platinum compounds, 53
Platinum-based combination
 chemotherapy, 106
PLCG2 expression, 154
Polymerase chain reaction (PCR), 239, 277
Post-operative chemotherapy, 66
Preoperative chemotherapy, 5, 7, 8, 9, 13,
 16, 17, 65, 104, 105
Prickle (PK) proteins, 153
Primary nephrectomy for WT, 104
Primary renal tumours in childhood, 4
Prm1, 164, 165, 169, 170, 171, 172, 173, 174,
 175, 176, 177
Prm3, 164, 165, 169, 177
Prognosis, 24, 44, 71
Proinflammatory cytokines, 218

Prominent cystic appearance, WT with, 16
Pronephros, 83
Prostaglandin E2, 199
Prostate cancer, 235, 242
Protein kinase C-related kinase/protein
 kinase novel (PRK/PKN), 168

R

Radiotherapy, 70
Rance, Thomas F., 44
Recessive tumor suppressor genes, 34
Recurrent disease, 52
Renal cell carcinomas, 16
Renal function in Wilms tumour
 survivors, 138
Renal tissue preservation, 64
Renal tumours, 4
Renal vein, ligation of, 54
Residual renal parenchyma, 67, 71
Retroperitoneal ERWT, 87
Rhabdoid tumour, 16

S

Schwartz equation, 137
Seldinger technique, 97
Signal transduction pathways, 150
SIOP WT 2001 trial, 50
Sipuleucel-T (Provenge), 115, 116
SIX2 (*Sine oculis homeobox 2* gene), 153
Six2-positive mesenchymal cells, 33
Small round blue cell tumours, 6
Smooth muscle (SM), 164
Snail upregulation, 238
Societe Internationale D'oncologie
 Pediatrique (SIOP), 9, 11, 44, 46, 48,
 52, 62
Solitary kidney, 135, 142
Sp1 binding, 246
Staging, 46

Index

Steinman, Ralph, 114
Stimulating protein (Sp) 1, 178
Stockholm working classification of renal tumors, 44
Strabismus (STBM), 153
Stromal-type WTs, 7, 16
Surgical management, 46
Syndromic tumors, 34
Systemic chemotherapy, 95

T

T lymphocytes, 193
T prostanoid receptor (TP), 164, 177
T prostanoid receptor (TP) α , 165, 166, 167, 169, 172, 174, 177
T prostanoid receptor (TP) β , 165, 166, 167, 169, 177
Tamm-Horsfall protein, 11
TBXA2R gene, 164, 165, 169, 172
Telomerase activity, 36
Telomere maintenance, 36
Telomere stability, 36
Temozolomide, 268
Tetramer analysis, immune monitoring with, 120
Therapeutic targets in WT, 200
Thoracic ERWT, 87
Thromboxane (TX) A_2 , 164, 167, 170
Thymosin beta-4, 217
Titanium clips, 49
TP53 gene, 8, 155
Transcatheter arterial chemoembolization (TACE), 95, 97, 99, 105
Transient catheter, 49
Trendelenburg, Frederick, 62
Tumor angiogenesis, WT1 and, 241
Tumor suppressor gene (TSG), 151, 237
Tumor-associated macrophages (TAMs), 193
Tumor-infiltrating leukocytes (TIL), 192

Tumor-infiltrating neutrophils (TINs), 193, 194
Types of WT, 192

U

U1242 glioblastoma cells, 266
U87MG cells, 266
Ultrasonic scalpel, 51
Ultrasonography (US), 45
Ultrasound examination of WTS, 140
Ultrasound with Doppler, 63
Unfavorable histology, 192
Unilateral nephrectomy for WT, 50
Unilateral WT (UWT), 132, 134, 135, 137

V

Varicocele, 45
Vascular endothelial growth factor (VEGF), 192, 196, 237, 241, 242, 243
Viable tumour, 6
Vincristine, 66, 87, 105
Vindesine, 98
Von Willebrand disease, 46

W

WAGR syndrome, 34, 44
Wilms, Carl Max Wilhelm, 44, 62
Wilms tumor 1 (WT1) protein, 236
Wilms tumor 1 gene (*WT1*), 153, 154
Wilms tumorigenesis, 33
Wilms' tumor (case), 119
Wilms' tumor 1 (WT1), 34, 116, 121, 133, 134, 169, 211, 212, 216, 219, 222, 235, 236, 237, 238, 240, 241, 261, 262, 266, 267, 274, 275, 277
Wnt signaling pathway, 150, 152, 153
WNT4 transcription, 153
WNT5A signaling, 154, 155

Index

WNT5B signaling, 154, 155

WNT6, 153

WNT9B, 153

Wolffian duct, 33

WT survivors (WTS), 131

WT1 antigen-specific CTLs (WT1-CTLs),
120, 121

WT1-expressing stem cell-like
cells, 222

WT2 gene, 34, 44

Doi: <http://dx.doi.org/10.15586/codon.wt.2016.ind>